November 8 from 3:30 pm – 4:15 pm EST
Innovation Theater B | Supported By: Genentech
Program Description
Expert-led review: Identifying treatment opportunities for patients with lupus nephritis
Taking place on November 8, 2026, at 3:30 PM EST in Innovation Theater B. Developed and offered by Genentech.
The treatment landscape for lupus nephritis continues to grow, giving clinicians more advanced therapy options. Evolving clinical guidance, including the latest from ACR, EULAR, and KDIGO, has made both which advanced therapy to use and when to initiate it equally critical decisions.
In this session, Dr. Alvin Wells will provide an in-depth overview of Camila, a 29-year-old private chef who has lupus nephritis. He will discuss Camila’s treatment history, her current presentation, and key decision points that led to starting an advanced therapy to help her achieve her treatment goals.
Attendees will be able to:
- Evaluate the latest data supporting a triple-therapy regimen for lupus nephritis
- Initiate early triple therapy with greater confidence
- Tailor a triple-therapy regimen to each patient’s individual needs
For healthcare professionals only. This program is developed and offered by Genentech. This is not an official program of the American College of Rheumatology.
ACR=American College of Rheumatology; EULAR=European Alliance of Associations for Rheumatology; KDIGO=Kidney Disease: Improving Global Outcomes.
Speakers
Presenter: Alvin Wells MD, PhD, FACR, FACP
American Medical Group
Director of Rheumatology
Destin, Florida